Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Phosphate binder (calcium-based) Pregnancy: US Pregnancy Category C. No adequate and well-controlled studies in pregnant women; calcium acetate treatment as recommended is not expected to harm the fetus if maternal calcium levels are properly monitored.

Calcium acetate

Brand names: Phosex, Renacet

Calcium acetate is an oral calcium-based phosphate binder used to control hyperphosphataemia in chronic kidney disease, particularly in patients on dialysis.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: 2 capsules (667 mg calcium acetate per capsule) with each meal — recommended initial dose for the adult dialysis patient
Route: Oral
Frequency: With each meal
Phosphate binder in dialysis patients. Increase the dose gradually to lower serum phosphorus to the target range, as long as hypercalcaemia does not develop; titrate every 2-3 weeks until an acceptable serum phosphorus level is reached. Most patients require 3-4 capsules with each meal. Monitor serum calcium twice weekly early in treatment during the dosage-adjustment period. Note: the eMC bundle for this id was the CLINIMIX parenteral-nutrition SPC (not the phosphate-binder indication); posology taken from US labelling.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Patients with hypercalcaemia

Side effects

  • Hypercalcaemia
  • Nausea
  • Vomiting

Interactions

  • May decrease the bioavailability of tetracyclines or fluoroquinolones (e.g. ciprofloxacin) — administer the interacting drug at least 1 hour before or at least 3 hours after calcium acetate, or consider monitoring blood levels
  • Avoid concurrent calcium supplements, including calcium-based nonprescription antacids
  • May aggravate digitalis (digoxin) toxicity via hypercalcaemia

Clinical monograph

How it works

Taken with food, it binds dietary phosphate in the gut to form insoluble, non-absorbed calcium phosphate, reducing phosphate absorption and lowering serum phosphate.

Prescribing in practice

  • It must be taken with meals to bind dietary phosphate; the principal risk is hypercalcaemia, so the overall calcium load must be limited to avoid vascular calcification.
  • Avoid in hypercalcaemia and use cautiously where calcium intake from all sources is already high, switching to a non-calcium binder if hypercalcaemia develops.
  • Separate administration from oral medicines whose absorption it reduces, including certain antibiotics, iron, levothyroxine and bisphosphonates.

Monitoring

Monitor serum calcium and phosphate regularly to maintain phosphate control while avoiding hypercalcaemia.

Counselling the patient

  • Take it with or just before food so it can soak up the phosphate in your meal.
  • Keep separate from other tablets such as some antibiotics, iron and thyroid medicine.
  • Report symptoms of a high calcium level such as nausea, constipation or confusion.

Evidence & guidelines

Phosphate binder use and calcium-balance considerations in CKD are guided by KDIGO and NICE CKD mineral and bone disorder recommendations.

Reference: NICE NG203; KDIGO CKD-MBD; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways